SecBot SecBot

ALVOW

Alvotech
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. N4· CIK 0001898416 Biotech & Drug Discovery
Warrants of Alvotech · ALVO stock page →
—
Market cap
$164.0M
Micro cap
1 year
−42.4%
from $8.13 · Oct 27
30 days
−23.9%
from $6.15
52-week range
$3.00–8.13
−42% from high · low Jun 2
Avg volume 20D
996.7K
Oct 5 spike 2.90M
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
4
analyzed by SecBot
SecBot read BULLISH 4 reports · latest
Balance 0 bearish · 1 bullish · 1 mixed · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/4
Strongest MIXED Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and a profit…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 0 trimmed or exited.

  • TrendDOWNTREND

    11% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
UBS Group AGDOUBLED1,155$266.00

Quarterly 13F filings are due 45 days after each quarter ends.

Washington

Corporate Lobbying

7 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
1,155 shares ($266.00)
Jun 8, 2026 SEC
Alvotech filed its Q1 2026 6-K, reporting total revenues of $105.9M (down 20% YoY from $132.8M) and a profit of $1.0M…
6-K — Impact 6/10
Jun 4, 2026 SEC
Alvotech resubmitted U.S. Biologics License Applications for AVT05 (biosimilar to Simponi/Simponi Aria) and AVT06…
6-K — Impact 6/10
May 11, 2026 SEC
Alvotech disclosed that the FDA completed a routine cGMP surveillance inspection at its Reykjavik facility, concluding…
6-K — Impact 4/10

SecBot reports

4 filings · 1 bullish · 0 bearish · 1 mixed · 2 neutral
All ALVOW filing & press-release reports (4)